Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetron
Thomas Ottoboni,1 Mark S Gelder,1 Erin O’Boyle2 1Heron Therapeutics, Inc., Redwood City, CA, USA; 2FibroGen, Inc., San Francisco, CA, USA Abstract: Granisetron and other 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are first-line agents for preventing chemotherapy-induced naus...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2014-12-01
|
| Series: | Journal of Experimental Pharmacology |
| Online Access: | http://www.dovepress.com/biochronomertrade-technology-and-the-development-of-apf530-a-sustained-peer-reviewed-article-JEP |